CD8A and melanoma: These results demonstrated that the administration of N-Pr-4-S-CAP stimulates a melanoma-specific CD8+ T cell response via immunogenic melanoma cell death and can be used as a prevention therapy against the recurrence of melanoma through the maintenance of anti-melanoma immunity after N-Pr-4-S-CAP-mediated CTI therapy.